PEM
MCID: PRT038
MIFTS: 53

Protein-Energy Malnutrition (PEM)

Categories: Metabolic diseases

Aliases & Classifications for Protein-Energy Malnutrition

MalaCards integrated aliases for Protein-Energy Malnutrition:

Name: Protein-Energy Malnutrition 12 77 56 45 15 74
Protein Energy Malnutrition 17
Pem 49

Classifications:



External Ids:

Disease Ontology 12 DOID:11801
ICD9CM 36 263.9
MeSH 45 D011502
NCIt 51 C34952
SNOMED-CT 69 72608005
ICD10 34 E46
UMLS 74 C0033677

Summaries for Protein-Energy Malnutrition

Disease Ontology : 12 A nutritional deficiency disease that is characterized by inadequate dietary protein and calories, which can have profound systemic effects including decreased metabolism, altered tissue distribution, compromised immunity, and impaired growth, and has material basis in dietary deprivation.

MalaCards based summary : Protein-Energy Malnutrition, also known as protein energy malnutrition, is related to marasmus and kwashiorkor, and has symptoms including cachexia and emaciation. An important gene associated with Protein-Energy Malnutrition is ALB (Albumin), and among its related pathways/superpathways are IL-1 Family Signaling Pathways and Dilated cardiomyopathy (DCM). The drugs chenodeoxycholic acid and Morphine have been mentioned in the context of this disorder. Affiliated tissues include prostate, brain and bone, and related phenotypes are adipose tissue and homeostasis/metabolism

Wikipedia : 77 Protein–energy malnutrition (PEM) is a form of malnutrition that is defined as a range of pathological... more...

Related Diseases for Protein-Energy Malnutrition

Diseases related to Protein-Energy Malnutrition via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
# Related Disease Score Top Affiliating Genes
1 marasmus 32.5 ALB IGF1 TF TTR
2 kwashiorkor 32.4 ALB GPT TF TTR
3 chronic fatigue syndrome 32.0 IGF1 IL6 TNF
4 keratomalacia 31.0 TF TTR
5 hypervitaminosis a 30.2 MGAM TTR
6 anorexia nervosa 30.0 IGF1 LEP TTR
7 liver cirrhosis 30.0 ALB GPT LEP TF TTR
8 fetal macrosomia 29.8 IGF1 LEP
9 viral hepatitis 29.8 ALB GPT TNF
10 fatty liver disease 29.6 IL6 LEP TNF
11 meningitis 29.5 ALB IL6 TNF
12 gastroenteritis 29.5 ALB IL6 TNF
13 deficiency anemia 29.5 ALB CP IL6 TF
14 kidney disease 29.5 ALB IL6 TF TTR
15 malaria 29.5 ALB IL6 TF TNF
16 alcoholic hepatitis 29.1 ALB GPT IL6 TNF
17 chronic kidney failure 28.9 ALB IGF1 IL6 LEP TF TTR
18 diabetes mellitus, noninsulin-dependent 28.6 ALB GPT IGF1 IL6 LEP TNF
19 diabetes mellitus 28.6 ALB CP IGF1 IL6 LEP TNF
20 liver disease 28.2 ALB CP GPT IL6 LEP TF
21 paramyloidosis 10.4 ALB TTR
22 epstein-barr virus hepatitis 10.4 ALB TF
23 meningitis and encephalitis 10.4 ALB CP
24 decubitus ulcer 10.4 ALB TTR
25 chronic inflammatory demyelinating polyneuropathy 10.4 TF TTR
26 yellow nail syndrome 10.4 ALB TF
27 median rhomboid glossitis 10.4 TF TTR
28 aleutian mink disease 10.4 ALB TTR
29 chronic ulcer of skin 10.4 ALB TTR
30 thyroid crisis 10.4 ALB TTR
31 hyperthyroxinemia 10.4 ALB TTR
32 blind loop syndrome 10.3 ALB TTR
33 hypochromic microcytic anemia 10.3 CP TF
34 ancylostomiasis 10.3 CP TF
35 autonomic nervous system disease 10.3 ALB TTR
36 pure red-cell aplasia 10.3 ALB TF
37 ariboflavinosis 10.3 ALB TF
38 benign essential hypertension 10.3 ALB MGAM
39 hepatic tuberculosis 10.3 ALB GPT
40 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.3
41 ischemia 10.3
42 hepatic coma 10.3 ALB GPT
43 retinitis pigmentosa 7 10.3 TF TTR
44 infantile liver failure syndrome 1 10.3 ALB GPT
45 dysentery 10.2 ALB TF TTR
46 testicular yolk sac tumor 10.2 ALB TF TTR
47 chronic graft versus host disease 10.2 ALB TNF
48 melancholia 10.2 TF TNF
49 haemophilus influenzae 10.2 TF TNF
50 uremia 10.2 ALB LEP TF

Comorbidity relations with Protein-Energy Malnutrition via Phenotypic Disease Network (PDN): (show top 50) (show all 151)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alzheimer Disease Anorexia Nervosa
Anxiety Atrophic Gastritis
Bacteremia 2 Bronchiectasis
Bronchitis Bronchopneumonia
Bullous Pemphigoid Candidiasis
Cardiac Arrest Cecal Benign Neoplasm
Celiac Disease 1 Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Cholestasis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Failure Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Ulcer of Skin
Chylomicron Retention Disease Colorectal Cancer
Conjunctivitis Crohn's Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Dental Caries
Dermatomycosis Disseminated Intravascular Coagulation
Duodenum Cancer Dyskinesia of Esophagus
Dysthymic Disorder Encephalopathy

Graphical network of the top 20 diseases related to Protein-Energy Malnutrition:



Diseases related to Protein-Energy Malnutrition

Symptoms & Phenotypes for Protein-Energy Malnutrition

UMLS symptoms related to Protein-Energy Malnutrition:


cachexia, emaciation

MGI Mouse Phenotypes related to Protein-Energy Malnutrition:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.65 CP IGF1 IL6 LEP TNF
2 homeostasis/metabolism MP:0005376 9.65 ALB CP IGF1 IL6 LEP MGAM
3 digestive/alimentary MP:0005381 9.63 ALB IL6 LEP PIGR TNF TTR
4 neoplasm MP:0002006 9.02 ALB IGF1 IL6 LEP TNF

Drugs & Therapeutics for Protein-Energy Malnutrition

Drugs for Protein-Energy Malnutrition (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
2
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
3
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
4
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 52485-79-7 644073 40400
6
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Lumefantrine Approved Phase 4 82186-77-4 6437380
9
Artemether Approved Phase 4 71963-77-4 68911 119380
10
Ethanol Approved Phase 4 64-17-5 702
11
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
12
Isoleucine Approved, Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
13 leucine Phase 4
14 valine Phase 4
15 Liver Extracts Phase 4,Phase 2,Phase 1,Not Applicable
16 Cathartics Phase 4
17 Laxatives Phase 4
18 Bile Acids and Salts Phase 4
19 Antimetabolites Phase 4,Phase 2,Phase 1
20 Anticholesteremic Agents Phase 4
21 Gastrointestinal Agents Phase 4,Phase 2
22 Colesevelam Hydrochloride Phase 4
23 Hypolipidemic Agents Phase 4
24 Glucagon-Like Peptide 1 Phase 4
25 Lipid Regulating Agents Phase 4
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2
28 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
29 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
30 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Narcotics Phase 4,Phase 3,Phase 2
33 Anesthetics Phase 4,Phase 3,Phase 2
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
36 Cyclooxygenase Inhibitors Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
38 Opiate Alkaloids Phase 4
39 Narcotic Antagonists Phase 4,Phase 3
40 Anesthetics, General Phase 4,Phase 3
41 Antimalarials Phase 4
42 Antiparasitic Agents Phase 4,Not Applicable
43 Artemether, Lumefantrine Drug Combination Phase 4
44 Antiprotozoal Agents Phase 4,Not Applicable
45
Acetaminophen Approved Phase 3,Phase 2,Phase 1 103-90-2 1983
46
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 2713 9552079
47
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
48
Lubiprostone Approved, Investigational Phase 3 136790-76-6 656719
49
Sodium oxybate Approved Phase 3 502-85-2 5360545
50
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
2 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
3 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
4 Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial Completed NCT02152592 Phase 4 PCM/Oxy1;PCM/Oxy2
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
7 Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer Recruiting NCT03849365 Phase 4 TOOKAD VTP
8 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children Recruiting NCT03453840 Phase 4 Artemether-lumefantrine
9 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
10 Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds Unknown status NCT00755989 Phase 3 morphine topical gel;placebo
11 Post-Approval Clinical Trial of the PCM® Cervical Disc Completed NCT01905930 Phase 3
12 PCM Cervical Disc System Completed NCT00578812 Phase 3
13 Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer Completed NCT01875393 Phase 3 TOOKAD® Soluble
14 Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Completed NCT01310894 Phase 3 TOOKAD® Soluble
15 Newborn Kit to Save Lives and Brains in Kenya Completed NCT02208960 Phase 3
16 Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients Completed NCT00561093 Phase 3 pentoxiphylline;Placebo pill imitating pentoxiphylline
17 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone Completed NCT00597428 Phase 3 Lubiprostone;Placebo
18 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. Completed NCT00423605 Phase 3 Xyrem®
19 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Completed NCT00371137 Phase 3 Xyrem®;Placebo
20 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed NCT00312572 Phase 3 Buprenorphine transdermal patch
21 Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
22 Paracetamol for Intrapartum Analgesia Unknown status NCT02578251 Phase 2 Paracetamol;Pethidine
23 Whole Body Cooling Using Phase Changing Material Unknown status NCT01138176 Phase 1, Phase 2
24 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
25 Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care Completed NCT01401101 Phase 2
26 Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed NCT01547806 Phase 2 Filgrastim;Plerixafor
27 Study Using WST11 in Patients With Localized Prostate Cancer Completed NCT00975429 Phase 2 WST11;WST11
28 Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer Completed NCT00946881 Phase 1, Phase 2 WST 11 -mediated -VTP
29 Study of WST11 in Patients With Localized Prostate Cancer Completed NCT00707356 Phase 2 WST11
30 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men Completed NCT01294319 Phase 2 Mifepristone;Placebo;Spironolactone;Combined;Dexamethasone
31 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT03414034 Phase 2 Onvansertib;Abiraterone;Prednisone
32 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Recruiting NCT03829410 Phase 1, Phase 2 Onvansertib;FOLFIRI
33 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). Recruiting NCT03303339 Phase 1, Phase 2 Onvansertib;Cytarabine;Decitabine
34 Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Recruiting NCT03315754 Phase 2 TOOKAD Soluble 4 mg/kg
35 A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
36 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
37 Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma Not yet recruiting NCT03908255 Phase 2 Branch Chain Amino Acid
38 Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma Terminated NCT00557830 Phase 2 Sorafenib Escalated Dose;Sorafenib Standard Dose
39 Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose Completed NCT03679442 Phase 1 N-acetylcysteine
40 Acceptability and Efficacy of 'Fish Surimi Peptide' in Under Five Children Suffering From Moderate Acute Malnutrition Completed NCT02272543 Phase 1
41 A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer Terminated NCT00779311 Phase 1 sorafenib;bevacizumab;mFOLFOX6 regimen
42 Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project) Unknown status NCT02273206 Not Applicable
43 The Impact of Perioperational Malnutrition on the Cost on Gastroenterological Cancer Patients Unknown status NCT00987883
44 Nutritional Rehabilitation in Senegalese HIV-infected Children and Adolescents Unknown status NCT03101852 Not Applicable
45 Effectiveness of Safe Drinking Water in Treatment of Severe Acute Malnutrition (Pakistan) Unknown status NCT02751476 Not Applicable
46 Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients Completed NCT00135590 Not Applicable
47 Clinical Performance of the Embrace Isothermal Mattress Completed NCT01425086
48 Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Completed NCT01873963
49 Study of Antioxidants and Oxidants in Malnourished Children Completed NCT00069134 Not Applicable
50 Energy Dense Formula to People Living in Old Peoples Home Completed NCT01259999 Not Applicable

Search NIH Clinical Center for Protein-Energy Malnutrition

Cochrane evidence based reviews: protein-energy malnutrition

Genetic Tests for Protein-Energy Malnutrition

Anatomical Context for Protein-Energy Malnutrition

MalaCards organs/tissues related to Protein-Energy Malnutrition:

42
Prostate, Brain, Bone, Kidney, Thyroid, Heart, Testes

Publications for Protein-Energy Malnutrition

Articles related to Protein-Energy Malnutrition:

(show top 50) (show all 709)
# Title Authors Year
1
A systematic review, meta-analysis and meta-regression of the prevalence of protein-energy malnutrition: associations with geographical region and sex. ( 30188972 )
2019
2
Zinc deficiency and severe protein-energy malnutrition in a child with atopic eczema. ( 30062797 )
2019
3
A systematic review and meta-analysis of the criterion validity of nutrition assessment tools for diagnosing protein-energy malnutrition in the older community setting (the MACRo study). ( 29102322 )
2018
4
Why Is the Skeleton Still in the Hospital Closet? A Look at the Complex Aetiology of Protein-Energy Malnutrition and Its Implications for the Nutrition Care Team. ( 29300418 )
2018
5
Protein-Energy Malnutrition and Outcomes of Hospitalizations for Heart Failure in the USA. ( 30612726 )
2018
6
Identifying reliable predictors of protein-energy malnutrition in hospitalized frail older adults: A prospective longitudinal study. ( 29579571 )
2018
7
Prospective associations of poor diet quality with long-term incidence of protein-energy malnutrition in community-dwelling older adults: the Health, Aging, and Body Composition (Health ABC) Study. ( 29529142 )
2018
8
Protein-Energy Malnutrition Exacerbates Stroke-Induced Forelimb Abnormalities and Dampens Neuroinflammation. ( 29397529 )
2018
9
Protein blend ingestion before allogeneic stem cell transplantation improves protein-energy malnutrition in patients with leukemia. ( 28964569 )
2017
10
An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition. ( 28934453 )
2017
11
Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice. ( 28860040 )
2017
12
Genetic Engineering: A Possible Strategy for Protein-Energy Malnutrition Regulation. ( 28828714 )
2017
13
Honey can repairing damage of liver tissue due to protein energy malnutrition through induction of endogenous stem cells. ( 28717326 )
2017
14
Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. ( 27862791 )
2017
15
Does protein energy malnutrition affect the outcome in Tunisian cirrhotic patients? ( 27532543 )
2016
16
Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. ( 27456231 )
2016
17
Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. ( 27311000 )
2016
18
Protein energy malnutrition associates with different types of hearing impairments in toddlers: Anemia increases cochlear dysfunction. ( 27240492 )
2016
19
Protein-energy malnutrition in the rehabilitation setting: Evidence to improve identification. ( 26921933 )
2016
20
Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease: Analysis Using Indirect Calorimetry. ( 26765430 )
2016
21
Protein-energy malnutrition at mid-adulthood does not imprint long-term metabolic consequences in male rats. ( 26133298 )
2016
22
The Arid Melancholy-Netherton Syndrome With Protein Energy Malnutrition. ( 27190931 )
2016
23
Protein-energy malnutrition is frequent and precocious in children with cri du chat syndrome. ( 26872355 )
2016
24
Evaluation of dental age in protein energy malnutrition children. ( 26538919 )
2015
25
Protein-Energy Malnutrition Causes Deficits in Motor Function in Adult Male Rats. ( 26423735 )
2015
26
Serum vitamin D status in children with protein-energy malnutrition admitted to a national referral hospital in Uganda. ( 26346815 )
2015
27
Seroprevalence rate of Poliovirus antibodies among the Healthy and Protein Energy Malnutrition children. ( 26101500 )
2015
28
Leucine supplementation improves acquired growth hormone resistance in rats with protein-energy malnutrition. ( 25909895 )
2015
29
Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection. ( 25754202 )
2015
30
Protein-energy malnutrition: a risk factor for various ailments. ( 24915388 )
2015
31
Maternal protein-energy malnutrition during early pregnancy in sheep impacts the fetal ornithine cycle to reduce fetal kidney microvascular development. ( 25077559 )
2014
32
Protein energy malnutrition increases arginase activity in monocytes and macrophages. ( 25392710 )
2014
33
Protein energy-malnutrition: does the in vitro zinc sulfate supplementation improve chromosomal damage repair? ( 25262017 )
2014
34
Determinants of protein-energy malnutrition in community-dwelling older adults: a systematic review of observational studies. ( 25257179 )
2014
35
Prevalence of protein-energy malnutrition in hospital patients over 75 years of age admitted for hip fracture. ( 24998085 )
2014
36
Protein-energy Malnutrition in Goitrous Schoolchildren of Isfahan, Iran. ( 24932384 )
2014
37
Protein energy malnutrition in India: the plight of our under five children. ( 24791240 )
2014
38
Free radicals and antioxidant status in protein energy malnutrition. ( 24790610 )
2014
39
Hematologic and bone marrow changes in children with protein-energy malnutrition. ( 23987917 )
2014
40
Effect of early childhood protein-energy malnutrition on permanent dentition dental caries. ( 24255941 )
2014
41
Protein-energy malnutrition developing after global brain ischemia induces an atypical acute-phase response and hinders expression of GAP-43. ( 25259609 )
2014
42
Missed opportunities in the diagnosis and management of protein energy malnutrition among children under 5 years in Wakiso district, Uganda. ( 25035810 )
2013
43
Cystic fibrosis: from protein-energy malnutrition to obesity with dyslipidemia. ( 24800027 )
2013
44
Methicillin-resistant Staphylococcus aureus carriage in infants with protein-energy malnutrition. ( 24502042 )
2013
45
Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice. ( 24200975 )
2013
46
Hepatoprotective and nephroprotective effects of Cnidoscolus aconitifolius in protein energy malnutrition induced liver and kidney damage. ( 24174819 )
2013
47
Porcine placenta mitigates protein-energy malnutrition-induced fatigue. ( 24035056 )
2013
48
A narrative review of recent progress in understanding the relationship between tuberculosis and protein energy malnutrition. ( 23942176 )
2013
49
Rutin (quercetin rutinoside) induced protein-energy malnutrition in chronic kidney disease, but quercetin acted beneficially. ( 23876017 )
2013
50
Protein-energy malnutrition induces an aberrant acute-phase response and modifies the circadian rhythm of core temperature. ( 23855272 )
2013

Variations for Protein-Energy Malnutrition

Expression for Protein-Energy Malnutrition

Search GEO for disease gene expression data for Protein-Energy Malnutrition.

Pathways for Protein-Energy Malnutrition

GO Terms for Protein-Energy Malnutrition

Cellular components related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 ALB CP GPT MGAM PIGR TF
2 extracellular region GO:0005576 9.61 ALB CP IGF1 IL6 LEP PIGR
3 blood microparticle GO:0072562 9.5 ALB CP TF
4 endoplasmic reticulum lumen GO:0005788 9.46 ALB CP IL6 TF
5 extracellular space GO:0005615 9.32 ALB CP GPT IGF1 IL6 LEP

Biological processes related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.9 ALB IGF1 IL6 LEP
2 post-translational protein modification GO:0043687 9.78 ALB CP IL6 TF
3 positive regulation of MAPK cascade GO:0043410 9.7 IGF1 IL6 LEP
4 platelet degranulation GO:0002576 9.67 ALB IGF1 TF
5 regulation of signaling receptor activity GO:0010469 9.65 IGF1 IL6 LEP TNF TTR
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.63 IGF1 LEP TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IGF1 IL6 LEP
8 positive regulation of cytokine production GO:0001819 9.59 LEP TNF
9 positive regulation of JAK-STAT cascade GO:0046427 9.58 IL6 LEP
10 negative regulation of neurogenesis GO:0050768 9.58 IL6 TNF
11 positive regulation of chemokine production GO:0032722 9.57 IL6 TNF
12 leukocyte tethering or rolling GO:0050901 9.56 LEP TNF
13 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.55 IGF1 TNF
14 positive regulation of glial cell proliferation GO:0060252 9.54 IL6 TNF
15 negative regulation of glucose import GO:0046325 9.51 LEP TNF
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 IGF1 IL6 TNF
17 positive regulation of neuroinflammatory response GO:0150078 9.4 IL6 TNF
18 bone mineralization involved in bone maturation GO:0035630 9.37 IGF1 LEP
19 retina homeostasis GO:0001895 9.33 ALB PIGR TF
20 negative regulation of lipid storage GO:0010888 9.13 IL6 LEP TNF
21 cellular protein metabolic process GO:0044267 9.1 ALB CP IGF1 IL6 TF TTR

Molecular functions related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 IGF1 LEP TTR

Sources for Protein-Energy Malnutrition

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....